STOCK TITAN

[Form 3] HARROW, INC. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Harrow, Inc. director/officer Francis William Mullery Jr. reported an initial beneficial ownership filing dated 10/06/2025. The filing discloses a stock option for 33,000 shares of common stock with an exercise price of $48.18. The option vests 25% after one year and the remainder in equal quarterly installments over the next three years, becoming fully vested and exercisable on 09/30/2029. The form was signed on 10/10/2025.

Harrow, Inc. direttore/ funzionario Francis William Mullery Jr. ha riportato una prima dichiarazione di possesso beneficio data 10/06/2025. La dichiarazione rivela una opzione su azioni per 33.000 azioni ordinarie con un prezzo di esercizio di $48.18. L'opzione matura al 25% dopo un anno e il restante in rate trimestrali uguali nei prossimi tre anni, diventando pienamente maturata ed esercitabile il 09/30/2029. Il modulo è stato firmato il 10/10/2025.

Harrow, Inc. el director/oficial Francis William Mullery Jr. informó una presentación de propiedad beneficiosa inicial fechada el 10/06/2025. La declaración divulga una opción de acciones para 33,000 acciones de acciones comunes con un precio de ejercicio de $48.18. La opción se consolida en un 25% después de un año y el resto en cuotas trimestrales iguales durante los próximos tres años, volviéndose plenamente adquirida y ejercitable el 09/30/2029. El formulario fue firmado el 10/10/2025.

Harrow, Inc. 이사/임원 Francis William Mullery Jr.는 2025년 10월 6일자로 기재된 최초의 수혜 소유 보고를 보고했습니다. 해당 보고서는 33,000주의 보통주에 대한 행사가격 $48.18의 스톡 옵션을 공개합니다. 옵션은 1년 후에 25%가 베스트되고 남은 부분은 향후 3년 동안 매 분기 고르게 vest되며, 2029년 9월 30일에 완전히 귀속되어 행사 가능해집니다. 양식은 2025년 10월 10일에 서명되었습니다.

Harrow, Inc. le directeur/agent Francis William Mullery Jr. a signalé un dépôt initial de propriété bénéficiaire daté du 10/06/2025. Le dépôt révèle une option d'achat pour 33 000 actions ordinaires à un prix d'exercice de $48.18. L'option acquiert 25% après un an et le reste par versements trimestriels égaux au cours des trois années suivantes, devenant entièrement acquise et exerçable le 09/30/2029. Le formulaire a été signé le 10/10/2025.

Harrow, Inc. Direktor/Beauftragter Francis William Mullery Jr. meldete eine anfängliche Meldung über wirtschaftliches Eigentum datiert vom 10/06/2025. Die Meldung offenbart eine Aktienoption für 33.000 Stammaktien mit einem Ausübungspreis von $48.18. Die Option vestet zu 25% nach einem Jahr und der Rest in gleichen vierteljährlichen Raten über die nächsten drei Jahre, wird vollständig vestet und ist am 09/30/2029 ausgeübtbar. Das Formular wurde am 10/10/2025 unterzeichnet.

Harrow, Inc. المدير/المسؤول Francis William Mullery Jr. أبلغ عن إيداع الملكية المفيدة الأول بتاريخ 10/06/2025. يكشف الإيداع عن خيار أسهم لـ 33,000 سهم من الأسهم العادية بسعر تمكين قدره $48.18. يتم vesting الخيار بنسبة 25% بعد سنة واحدة والباقي على أقساط ربع سنوية متساوية على مدى الثلاث سنوات القادمة، ليصبح مُكتمل الاستحقاق وقابلاً للتنفيذ في 09/30/2029. تم توقيع النموذج في 10/10/2025.

Harrow, Inc. 董事/官员 Francis William Mullery Jr. 报告了日期为 2025/10/06 的初始受益所有权申报。该申报披露了一项 33,000 股普通股的股票期权,行权价为 $48.18。该期权在一年后归属 25%,其余部分在接下来的三年内按季度等额分期归属,至 2029/09/30 时完全归属并可行使。该表格在 2025/10/10 签署。

Positive
  • Time‑based vesting (25% after one year, then quarterly) encourages retention through 09/30/2029
  • Clear exercise price disclosed at $48.18, enabling transparent valuation of the option
Negative
  • None.

Insights

Officer received a time‑based option for 33,000 shares at $48.18, standard vesting.

This grant aligns management incentives with shareholder value by tying potential gain to future stock performance through a multi‑year vesting schedule. The initial 25% cliff followed by quarterly vesting over three years is a common approach to retain executives and link pay to tenure.

The main dependencies are future stock price and continued service until full vesting on 09/30/2029. Investors should note the $48.18 exercise price relative to current market levels when assessing potential dilution or incentive alignment within the next 20252029 timeframe.

Harrow, Inc. direttore/ funzionario Francis William Mullery Jr. ha riportato una prima dichiarazione di possesso beneficio data 10/06/2025. La dichiarazione rivela una opzione su azioni per 33.000 azioni ordinarie con un prezzo di esercizio di $48.18. L'opzione matura al 25% dopo un anno e il restante in rate trimestrali uguali nei prossimi tre anni, diventando pienamente maturata ed esercitabile il 09/30/2029. Il modulo è stato firmato il 10/10/2025.

Harrow, Inc. el director/oficial Francis William Mullery Jr. informó una presentación de propiedad beneficiosa inicial fechada el 10/06/2025. La declaración divulga una opción de acciones para 33,000 acciones de acciones comunes con un precio de ejercicio de $48.18. La opción se consolida en un 25% después de un año y el resto en cuotas trimestrales iguales durante los próximos tres años, volviéndose plenamente adquirida y ejercitable el 09/30/2029. El formulario fue firmado el 10/10/2025.

Harrow, Inc. 이사/임원 Francis William Mullery Jr.는 2025년 10월 6일자로 기재된 최초의 수혜 소유 보고를 보고했습니다. 해당 보고서는 33,000주의 보통주에 대한 행사가격 $48.18의 스톡 옵션을 공개합니다. 옵션은 1년 후에 25%가 베스트되고 남은 부분은 향후 3년 동안 매 분기 고르게 vest되며, 2029년 9월 30일에 완전히 귀속되어 행사 가능해집니다. 양식은 2025년 10월 10일에 서명되었습니다.

Harrow, Inc. le directeur/agent Francis William Mullery Jr. a signalé un dépôt initial de propriété bénéficiaire daté du 10/06/2025. Le dépôt révèle une option d'achat pour 33 000 actions ordinaires à un prix d'exercice de $48.18. L'option acquiert 25% après un an et le reste par versements trimestriels égaux au cours des trois années suivantes, devenant entièrement acquise et exerçable le 09/30/2029. Le formulaire a été signé le 10/10/2025.

Harrow, Inc. Direktor/Beauftragter Francis William Mullery Jr. meldete eine anfängliche Meldung über wirtschaftliches Eigentum datiert vom 10/06/2025. Die Meldung offenbart eine Aktienoption für 33.000 Stammaktien mit einem Ausübungspreis von $48.18. Die Option vestet zu 25% nach einem Jahr und der Rest in gleichen vierteljährlichen Raten über die nächsten drei Jahre, wird vollständig vestet und ist am 09/30/2029 ausgeübtbar. Das Formular wurde am 10/10/2025 unterzeichnet.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Mullery Francis William Jr

(Last) (First) (Middle)
C/O HARROW, INC.
1A BURTON HILLS SUITE 200

(Street)
NASHVILLE TN 37215

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/06/2025
3. Issuer Name and Ticker or Trading Symbol
HARROW, INC. [ HROW ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, ImprimisRx
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)(1) (1) 09/30/2035 Common stock 33,000 $48.18 D
Explanation of Responses:
1. The shares subject to the option shall vest according to the following schedule: 25% of the shares shall vest at the one-year anniversary of the date of grant, and the remaining shares shall vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on September 30, 2029.
Remarks:
Exhibit 24 - POWER OF ATTORNEY
/s/ Andrew R. Boll as Attorney in Fact for Francis Mullery 10/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Francis Mullery Jr. report on the Form 3 for HROW?

He reported a stock option for 33,000 shares with an exercise price of $48.18 and a vesting schedule that makes it fully exercisable on 09/30/2029.

When was the Form 3 event dated for HROW?

The event requiring the statement is dated 10/06/2025, with the form signed on 10/10/2025.

What is the vesting schedule for the option disclosed by HROW Form 3?

Vesting is 25% at the one‑year anniversary of the grant, then quarterly over the next three years until fully vested on 09/30/2029.

How many shares underlie the derivative security reported on HROW Form 3?

The derivative security underlies 33,000 shares of common stock.

What is the significance of the exercise price on the Form 3 for HROW?

The exercise price is $48.18, which determines the cost to convert the option into common shares and is a key input for option valuation and potential dilution analysis.
Harrow Health Inc

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.50B
31.18M
15.72%
57.42%
13.38%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE